Recurrence Data for Narrow Band Imaging™ (NBI™) Technology Show Value in the Fight Against Non-Muscle Invasive Bladder Cancer featuring Vesica AI
Recent start-up activity around NBI technology and bladder cancer was recognized by Olympus in its selection of Vesica AI, a promising medical startup company, as the winner of the inaugural Olympus Asia Pacific Innovation Program (OAIP). Vesica AI was chosen from a field of four finalists for its innovative AI-based clinical visualization software that supports and enhances the early detection of bladder cancer through the cystoscopy procedure. Vesica AI is the result of a collaboration between the University of Tsukuba Hospital in Ibaraki prefecture, Japan, and the National Institute of Advanced Industrial Science and Technology (AIST), a Japanese public agency promoting scientific development. As the winning innovator, Vesica AI will receive grant funding of $75,000 as well as an exclusive mentorship program with key thought leaders from Olympus. The mentorship program will connect Vesica AI with experts from Olympus in meaningful ways that aim to support the future success of the company.
